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Abstract
In our country, world hepatitis day (28th May 2013)
was observed as a liver cancer day to draw global
attention on the global health menace caused by
Hepatocellular carcinoma (HCC). This is the right time
to write a review article to apprise the nation of this
growing burden of HCC caused most commonly by
viruses in our country.
Pakistan is also recognized as one of the countries of the
world where hepatitis C virus (HCV) is endemic. Recent
large national surveys suggest an overall HCV prevalence
of 4.8% and that of HBV as 2.5%. There are however
communities where the sero-prevalence of HCV can be as
high as 23%. No wonder that chronic liver disease is the
fifth most common reason for morbidity and mortality in
the country and Pakistan has been perhaps accurately
called a "cirrhotic state". Hence majority of such patients
are at risk of developing HCC.
Keywords: Hepatocellular carcinoma, Cirrhosis, Chronic
liver disease, Hepatitis B, D and C.
Introduction
Hepatocellular carcinoma (HCC) i-e Liver cancer has been
one of the most important cancers in the world. As per
world health organization (WHO) statistics (2000),
globally there are at least 564,000 new cases of HCC per
year and among them 400,000 develop in men.1
Unfortunately HCC is the one of the least curable
malignancies.2 Hepatocellular carcinoma (HCC),
accounting for 5% of cancers globally, is ranked as the 6th
most common cancer and the 3rd leading cause of
cancer-related death worldwide. The incidence of HCC
may continue increasing over the next 20 years and to
peak around 2030.3 HCC is fifth most common cancer
among men and second leading cause of cancer related
death in world with highest case fatality rate.4 Among
women, HCC is the 7th most common cancer and 6th
most common cancer related death.4 In Pakistan
prevalence of HCC varies from 3.7%-16% of malignant
tumours and most common cause of HCC is viral hepatitis
B, C and D related cirrhosis. In Pakistan approximately 87%
of HCC is caused by viral hepatitis either C (68%) or B
related cirrhosis (22%) similarly another study from
Hyderabad Sindh Pakistan had also shown high burden of
viral associated HCC (HCV 66% and HBV 43%).5 Recently a
study from Karachi had shown the increasing number of
admissions related to HCC and simultaneously showing
highest burden of viral associated HCC. According to this
report most of the cases are diagnosed at a very late stage
of the disease when options are very limited for cure and
less than 1% undergo resection.6
The incidence of HCC varies between diverse
geographical regions between countries or geo economic
zones within countries. This is a common cancer in the
Asia pacific region and Africa with age standardized
incidence of 14-36 per 100,000 men and this is much
lower than other subcontinents such as Australia, North
America and Europe.1
Most cases of HCC (approximately 85%) occur in the
developing world (Sub-Saharan Africa and Eastern Asia)
and among them 80% are due to chronic viral hepatitis B
and C Figure-1.7
Worldwide, an estimated two billion people have been
infected with the hepatitis B virus and more than 240
million have chronic (long-term) liver infections. About
600 000 people die every year due to the acute or chronic
consequences of hepatitis B.8
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Figure-1: Global map for HCC showing etiology.14
Every year, 3-4 million people are infected with the
hepatitis C virus. About 150 million people are chronically
infected and at risk of developing liver cirrhosis and/or
liver cancer. More than 350 000 people die from hepatitis
C-related liver diseases every year. Hepatitis C is found
worldwide. Countries with high rates of chronic infection
are Egypt (22%), Pakistan (4.8%) and China (3.2%). The
main mode of transmission in these countries is
attributed to unsafe injections or by using contaminated
equipments.9
Recently a nationwide conducted survey for prevalence of
HBV and HCV infection along with their risk factors in
Pakistan had shown moderate to high prevalence and
most common risk factor was use of unsafe injection.10
Pakistan is a sovereign country in South Asia and the sixth
most populous country in the world with population of
over 180 million people.11
Therefore it is assumed that incidence of HCC is expected
to rise as consequence of high incidence of HBV and HCV
in last quarter of last century and there is an average lag
time between virus acquisition and development of
cirrhosis which in turn lead to cancer in some cases. This
trend is also observed in Pakistan as shown by study in
Pakistan which confirmed that rising trend of HCC related
admission in tertiary care hospitals.6
Globally men are more likely to develop HCC than women
and a similar trend is also seen in Pakistan.2,12 Globally,
HCC is rarely seen in the first 4 decades of life except in
South Asia where prevalence of viral hepatitis associated
cirrhosis is high. Hence age adjusted incidence of HCC in
Pakistan is 5.7 for men and 3.7 for women.12
Risk factors: Multiple risk factors have been identified for
the development of hepatocellular carcinoma (HCC).
These include viral hepatitis (HBV, HCV), hereditary
haemochromatosis and cirrhosis of almost any cause.13
The relative importance of viral hepatitis in etiology of
HCC fluctuates significantly from one part of world to
another region.14
Hepatitis B: This infection has the peculiarity of
developing HCC even in the absence of cirrhosis, however
70-90% of the patients with HBV who develop HCC would
have cirrhosis.15 Apart from cirrhosis, there are other
factors associated with HBV, which play some role in
developing HCC. These factors include viral load, presence
of Hepatitis Be Ag (HBeAg) and presence of hepatitis B
surface Antigen (HBsAg).16 Co- infection of HBV with HCV
or HDV is associated with increased risk of HCC. These
patients with co infection had poorer outcome as
compared to mono-infection.17
Hepatitis C: There is a strong association between chronic
hepatitis C infection and HCC but the underlying
mechanism is unclear. HCV infection is the most common
cause of cirrhosis18 and HCC in Pakistan like in other
countries such as India, Japan, European countries and
also in North America.1,13,19 A prospective study from
Taiwan had shown 24% cumulative lifetime risk of HCC for
men and 17% women of age group 30-65 years.20
Cirrhosis: Patients with chronic liver disease due to any
cause will have an increased risk of HCC. Compensated
cirrhotic patients are believed to have a 1-8% annual
incidence of HCC.21
Environmental toxins: Environmental toxins like aflatoxin,
betel nut chewing and contaminated drinking water may
be contributing to the pathogenesis of HCC. However
their contribution to the world wide disease burden of
HCC is minimal.22,23
Diabetes mellitus (DM) and Non Alcoholic fatty liver
disease (NAFLD): Population based studies as well as
multiple systemic reviews had shown strong association
of DM with HCC. A systematic review that included a total
of 49 case-control and cohort studies estimated that the
risk was increased by approximately 2.2-fold (risk ratio 2.2;
95% CI 1.7-3.0), although few studies adjusted for diet and
obesity.24,25 Another meta-analysis comprising 14
epidemiologic studies found an increased risk of HCC
among diabetes patients (relative risk of 1.9).26 In Pakistan
around 6% of the population is suffering from diabetes
hence this is also a great threat to develop HCC in this
country.27
There is rising evidence that NAFLD signifies an
increasingly frequent underlying liver disease in patients
with HCC. It is likely that NAFLD causes HCC via cirrhosis,
although the exact pathogenesis has not yet been
determined. One study found that HCC in NASH was
associated with obesity, diabetes, hypertension and male
sex.28
Similar situation is found in Pakistan for diabetes and
obesity as shown by Jafar et al in their study. According to
this study about a quarter of Pakistani population is
overweight or obese.29 Therefore Pakistani population is
at higher risk for non B non C associated cirrhosis and
ultimately leading to HCC.
Diagnosis: Timely diagnosis of this deadly disease can be
curative if the patientswho are at risk of developing theHCC
will be enrolled into the regular surveillance programme.30
Hence early diagnosis of hepatocellular carcinoma (HCC) is
feasible because of its potential of developing in the
background of well known, readily identifiable and
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potentially avoidable
environmental risk factors.
International societies like
American association for the
studyof liver disease (AASLD) and
European Association for the
study of liver (EASL) disease
recommend semiannually an
Ultrasound liver and serumAFP.31
AASLD guidelines recommend
that amass found incidentally or
on screening in CLD patients is
likely to be HCC and Algorithm
for investigation of HCC is
shown in Figure-2.32
Management (Figure-3):
Historically majority of the
patients with HCC were
diagnosed in very late stages
when the patients were
symptomatic and had variable
degree of impairment of liver
functions.32 We assume that this
is still the case in our country
where patients are unfortunately
diagnosed late when no
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Figure-2: Diagnostic algorithm for suspected HCC. (CT: Computerized tomography, MRI: Magnetic resonance imaging, US:
Ultrasound).32
Figure-3: BCLC staging system and treatment allocation.32
effective treatment can be offered to improve survival.
Based on better surveillance programme, these patients
can be picked early and definitive or curative therapy
(surgical resection or radiofrequency ablation) can be
given or they can be offered a liver transplant or palliative
therapy like Trans-arterial chemoembolization (TACE).
Prevention
HCC prevention due to HBV infection: Vaccine for hepatitis
B (produced by recombinant DNA technology) was first
licensed in United States in 1981. The vaccine is
administered in a three doses series with good efficacy
and safety.14,33 HBV vaccine within 12-24 hours after birth,
followed by a 3 dose regimen, had shown significant
effect in prevention of vertical transmission of HBV
common in Asia.33
Recently decline in incidence of HCC and its associated
mortality has been confirmed in Taiwan population where
first HBV immunization programme was established in
1984.34
In 1992, world health organization (WHO) recommended
the addition of HBV vaccine into national immunization
programme. Among the 192, 158 member nations had
implemented the infant HBV vaccine programme by year
2005 and 62% of these countries claimed >80%
coverage.14 In Pakistan HBV vaccine was incorporated in
July 2001. One of the studies from Karachi had shown 86%
of health care worker to be vaccinated.35 In Pakistan,
vaccination should be targeted to the high risk persons
like intravenous drug abusers, sex workers, patient on
regular dialysis and family members of index cases of HBV
infection.
Other strategies include the avoidance of reuse of used
injections or unnecessary injections, use of new blade or
razor for each person at barber shop, avoiding homo or
heterosexual malpractices. Physicians should hold health
awareness session on preventing strategies for blood
borne infection.
HCC prevention due to HCV infection: there is no such
vaccine for HCV infection however research is going on to
develops the new prophylactic and therapeutic vaccine.
In the absence of vaccine for HCV, its prevention is more
difficult than the prevention of HBV hence requiring the
integrated strategies including the safe injection practices
and avoidance of unnecessary injection, routine
screening for blood before donation, avoiding going to
non-qualified dental doctors for dental procedures, ear
piercing or circumcision to be done by a certified doctor
with clean instruments and proper disposal of used
needles.
Regarding HCV infection, if it is cured successfully in time
before the development of cirrhosis, both cirrhosis and
HCC can be prevented.36
Other causes of cirrhosis: All the other conditions
(alcoholic liver disease, non alcoholic liver disease,
autoimmune hepatitis, primary biliary cirrhosis, primary
sclerosing cholangitis etc), which can potentially lead to
cirrhosis and ultimately HCC, should be timely managed,
to substantially reduce the risk of HCC.
Avoidance of environmental risk factors like aflatoxins
which is produced by strains of Aspergilus, can also
decrease the incidence of HCC.37
Good glycaemic control in diabetic patients with
antidiabetic medications like thiazolidinedione or
metformin has been associated with a decreased risk for
HCC.24
Conclusion
It is established that Pakistan is a poor country with
scarcity of resources and with high burden of all the risk
factors for HCC, therefore a big challenge of high burden
of HCC is confronted. Unfortunately majority of these
patients with HCC are diagnosed late with high mortality
and morbidity hence they are left with palliative
treatment only. Even the treatment modalities are not
available in major cities of Pakistan except in few selected
centers where only high affluent people can reach. We
therefore assume that HCC will be the next big threat to
Pakistan. Our physicians should be made aware of this
menace and should be taught about the surveillance for
HCC because regular surveillance for HCC will detect HCC
at an early stage where some curative options can be
availed. This is the time that we can raise a voice against
this menace which is causing untimely mortality and
morbidity. This is a potentially preventable tumour by
vaccinating the masses for HBV and adopting prevention
strategies for HCV infection.
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